Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market 2022 by Company, Regions, Type and Application, Forecast to 2028

Page: 102

Published Date: 10 Jan 2022

Category: Medical Care

PDF Download

Get FREE Sample

Customize Request

Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags

Description

The Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics market size is estimated to be worth US$ 18360 million in 2021 and is forecast to a readjusted size of USD 24470 million by 2028 with a CAGR of 4.2% during review period. Pediatric and Adolescents accounting for  % of the Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics global market in 2021, is projected to value USD  million by 2028, growing at a  % CAGR in next six years. While Stimulants segment is altered to a  % CAGR between 2022 and 2028.

Global key companies of Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics include Pfizer, GSK, Eli Lilly, Novartis, and Johnson & Johnson, etc. In terms of revenue, the global top four players hold a share over  % in 2021.

Market segmentation
Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
    Stimulants
    Non-stimulants

Market segment by Application, can be divided into
    Pediatric and Adolescents
    Adults

Market segment by players, this report covers
    Pfizer
    GSK
    Eli Lilly
    Novartis
    Johnson & Johnson
    Mallinckrodt
    Hisamitsu
    UCB
    Takeda
    Purdue Pharma
    Impax Laboratories

Market segment by regions, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
    South America (Brazil, Argentina, Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics, with revenue, gross margin and global market share of Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics from 2019 to 2022.
Chapter 3, the Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics research findings and conclusion, appendix and data source.

Table of Contents

1 Market Overview
    1.1 Product Overview and Scope of Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics
    1.2 Classification of Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics by Type
        1.2.1 Overview: Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Type: 2017 Versus 2021 Versus 2028
        1.2.2 Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Share by Type in 2021
        1.2.3 Stimulants
        1.2.4 Non-stimulants
    1.3 Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market by Application
        1.3.1 Overview: Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Application: 2017 Versus 2021 Versus 2028
        1.3.2 Pediatric and Adolescents
        1.3.3 Adults
    1.4 Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size & Forecast
    1.5 Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size and Forecast by Region
        1.5.1 Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Region: 2017 VS 2021 VS 2028
        1.5.2 Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Region, (2017-2022)
        1.5.3 North America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size and Prospect (2017-2028)
        1.5.4 Europe Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size and Prospect (2017-2028)
        1.5.5 Asia-Pacific Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size and Prospect (2017-2028)
        1.5.6 South America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size and Prospect (2017-2028)
        1.5.7 Middle East and Africa Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size and Prospect (2017-2028)
    1.6 Market Drivers, Restraints and Trends
        1.6.1 Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Drivers
        1.6.2 Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Restraints
        1.6.3 Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Trends Analysis

2 Company Profiles
    2.1 Pfizer
        2.1.1 Pfizer Details
        2.1.2 Pfizer Major Business
        2.1.3 Pfizer Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product and Solutions
        2.1.4 Pfizer Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.1.5 Pfizer Recent Developments and Future Plans
    2.2 GSK
        2.2.1 GSK Details
        2.2.2 GSK Major Business
        2.2.3 GSK Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product and Solutions
        2.2.4 GSK Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.2.5 GSK Recent Developments and Future Plans
    2.3 Eli Lilly
        2.3.1 Eli Lilly Details
        2.3.2 Eli Lilly Major Business
        2.3.3 Eli Lilly Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product and Solutions
        2.3.4 Eli Lilly Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.3.5 Eli Lilly Recent Developments and Future Plans
    2.4 Novartis
        2.4.1 Novartis Details
        2.4.2 Novartis Major Business
        2.4.3 Novartis Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product and Solutions
        2.4.4 Novartis Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.4.5 Novartis Recent Developments and Future Plans
    2.5 Johnson & Johnson
        2.5.1 Johnson & Johnson Details
        2.5.2 Johnson & Johnson Major Business
        2.5.3 Johnson & Johnson Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product and Solutions
        2.5.4 Johnson & Johnson Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.5.5 Johnson & Johnson Recent Developments and Future Plans
    2.6 Mallinckrodt
        2.6.1 Mallinckrodt Details
        2.6.2 Mallinckrodt Major Business
        2.6.3 Mallinckrodt Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product and Solutions
        2.6.4 Mallinckrodt Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.6.5 Mallinckrodt Recent Developments and Future Plans
    2.7 Hisamitsu
        2.7.1 Hisamitsu Details
        2.7.2 Hisamitsu Major Business
        2.7.3 Hisamitsu Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product and Solutions
        2.7.4 Hisamitsu Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.7.5 Hisamitsu Recent Developments and Future Plans
    2.8 UCB
        2.8.1 UCB Details
        2.8.2 UCB Major Business
        2.8.3 UCB Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product and Solutions
        2.8.4 UCB Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.8.5 UCB Recent Developments and Future Plans
    2.9 Takeda
        2.9.1 Takeda Details
        2.9.2 Takeda Major Business
        2.9.3 Takeda Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product and Solutions
        2.9.4 Takeda Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.9.5 Takeda Recent Developments and Future Plans
    2.10 Purdue Pharma
        2.10.1 Purdue Pharma Details
        2.10.2 Purdue Pharma Major Business
        2.10.3 Purdue Pharma Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product and Solutions
        2.10.4 Purdue Pharma Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.10.5 Purdue Pharma Recent Developments and Future Plans
    2.11 Impax Laboratories
        2.11.1 Impax Laboratories Details
        2.11.2 Impax Laboratories Major Business
        2.11.3 Impax Laboratories Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product and Solutions
        2.11.4 Impax Laboratories Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.11.5 Impax Laboratories Recent Developments and Future Plans

3 Market Competition, by Players
    3.1 Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Share by Players (2019, 2020, 2021, and 2022)
    3.2 Market Concentration Rate
        3.2.1 Top 3 Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Players Market Share in 2021
        3.2.2 Top 10 Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Players Market Share in 2021
        3.2.3 Market Competition Trend
    3.3 Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Players Head Office, Products and Services Provided
    3.4 Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Mergers & Acquisitions
    3.5 Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics New Entrants and Expansion Plans

4 Market Size Segment by Type
    4.1 Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Market Share by Type (2017-2022)
    4.2 Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Forecast by Type (2023-2028)

5 Market Size Segment by Application
    5.1 Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Share by Application (2017-2022)
    5.2 Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Forecast by Application (2023-2028)

6 North America by Country, by Type, and by Application
    6.1 North America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Type (2017-2028)
    6.2 North America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Application (2017-2028)
    6.3 North America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country
        6.3.1 North America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Country (2017-2028)
        6.3.2 United States Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size and Forecast (2017-2028)
        6.3.3 Canada Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size and Forecast (2017-2028)
        6.3.4 Mexico Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size and Forecast (2017-2028)

7 Europe by Country, by Type, and by Application
    7.1 Europe Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Type (2017-2028)
    7.2 Europe Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Application (2017-2028)
    7.3 Europe Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country
        7.3.1 Europe Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Country (2017-2028)
        7.3.2 Germany Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size and Forecast (2017-2028)
        7.3.3 France Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size and Forecast (2017-2028)
        7.3.4 United Kingdom Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size and Forecast (2017-2028)
        7.3.5 Russia Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size and Forecast (2017-2028)
        7.3.6 Italy Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size and Forecast (2017-2028)

8 Asia-Pacific by Region, by Type, and by Application
    8.1 Asia-Pacific Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Type (2017-2028)
    8.2 Asia-Pacific Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Application (2017-2028)
    8.3 Asia-Pacific Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Region
        8.3.1 Asia-Pacific Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Region (2017-2028)
        8.3.2 China Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size and Forecast (2017-2028)
        8.3.3 Japan Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size and Forecast (2017-2028)
        8.3.4 South Korea Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size and Forecast (2017-2028)
        8.3.5 India Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size and Forecast (2017-2028)
        8.3.6 Southeast Asia Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size and Forecast (2017-2028)
        8.3.7 Australia Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size and Forecast (2017-2028)

9 South America by Country, by Type, and by Application
    9.1 South America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Type (2017-2028)
    9.2 South America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Application (2017-2028)
    9.3 South America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country
        9.3.1 South America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Country (2017-2028)
        9.3.2 Brazil Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size and Forecast (2017-2028)
        9.3.3 Argentina Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size and Forecast (2017-2028)

10 Middle East & Africa by Country, by Type, and by Application
    10.1 Middle East & Africa Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Type (2017-2028)
    10.2 Middle East & Africa Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Application (2017-2028)
    10.3 Middle East & Africa Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country
        10.3.1 Middle East & Africa Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Country (2017-2028)
        10.3.2 Turkey Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size and Forecast (2017-2028)
        10.3.3 Saudi Arabia Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size and Forecast (2017-2028)
        10.3.4 UAE Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size and Forecast (2017-2028)

11 Research Findings and Conclusion

12 Appendix
    12.1 Methodology
    12.2 Research Process and Data Source
    12.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Type, (USD Million), 2017 VS 2021 VS 2028
    Table 2. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Application, (USD Million), 2017 VS 2021 VS 2028
    Table 3. Global Market Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)
    Table 4. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (USD Million) by Region (2017-2022)
    Table 5. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Share by Region (2023-2028)
    Table 6. Pfizer Corporate Information, Head Office, and Major Competitors
    Table 7. Pfizer Major Business
    Table 8. Pfizer Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product and Solutions
    Table 9. Pfizer Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 10. GSK Corporate Information, Head Office, and Major Competitors
    Table 11. GSK Major Business
    Table 12. GSK Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product and Solutions
    Table 13. GSK Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 14. Eli Lilly Corporate Information, Head Office, and Major Competitors
    Table 15. Eli Lilly Major Business
    Table 16. Eli Lilly Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product and Solutions
    Table 17. Eli Lilly Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 18. Novartis Corporate Information, Head Office, and Major Competitors
    Table 19. Novartis Major Business
    Table 20. Novartis Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product and Solutions
    Table 21. Novartis Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 22. Johnson & Johnson Corporate Information, Head Office, and Major Competitors
    Table 23. Johnson & Johnson Major Business
    Table 24. Johnson & Johnson Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product and Solutions
    Table 25. Johnson & Johnson Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 26. Mallinckrodt Corporate Information, Head Office, and Major Competitors
    Table 27. Mallinckrodt Major Business
    Table 28. Mallinckrodt Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product and Solutions
    Table 29. Mallinckrodt Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 30. Hisamitsu Corporate Information, Head Office, and Major Competitors
    Table 31. Hisamitsu Major Business
    Table 32. Hisamitsu Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product and Solutions
    Table 33. Hisamitsu Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 34. UCB Corporate Information, Head Office, and Major Competitors
    Table 35. UCB Major Business
    Table 36. UCB Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product and Solutions
    Table 37. UCB Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 38. Takeda Corporate Information, Head Office, and Major Competitors
    Table 39. Takeda Major Business
    Table 40. Takeda Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product and Solutions
    Table 41. Takeda Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 42. Purdue Pharma Corporate Information, Head Office, and Major Competitors
    Table 43. Purdue Pharma Major Business
    Table 44. Purdue Pharma Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product and Solutions
    Table 45. Purdue Pharma Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 46. Impax Laboratories Corporate Information, Head Office, and Major Competitors
    Table 47. Impax Laboratories Major Business
    Table 48. Impax Laboratories Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product and Solutions
    Table 49. Impax Laboratories Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 50. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)
    Table 51. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Share by Players (2019, 2020, 2021, and 2022)
    Table 52. Breakdown of Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics by Company Type (Tier 1, Tier 2 and Tier 3)
    Table 53. Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Players Head Office, Products and Services Provided
    Table 54. Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Mergers & Acquisitions in the Past Five Years
    Table 55. Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics New Entrants and Expansion Plans
    Table 56. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (USD Million) by Type (2017-2022)
    Table 57. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Share by Type (2017-2022)
    Table 58. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Forecast by Type (2023-2028)
    Table 59. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Application (2017-2022)
    Table 60. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Forecast by Application (2023-2028)
    Table 61. North America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Type (2017-2022) & (USD Million)
    Table 62. North America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Type (2023-2028) & (USD Million)
    Table 63. North America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Application (2017-2022) & (USD Million)
    Table 64. North America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Application (2023-2028) & (USD Million)
    Table 65. North America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Country (2017-2022) & (USD Million)
    Table 66. North America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Country (2023-2028) & (USD Million)
    Table 67. Europe Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Type (2017-2022) & (USD Million)
    Table 68. Europe Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Type (2023-2028) & (USD Million)
    Table 69. Europe Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Application (2017-2022) & (USD Million)
    Table 70. Europe Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Application (2023-2028) & (USD Million)
    Table 71. Europe Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Country (2017-2022) & (USD Million)
    Table 72. Europe Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Country (2023-2028) & (USD Million)
    Table 73. Asia-Pacific Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Type (2017-2022) & (USD Million)
    Table 74. Asia-Pacific Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Type (2023-2028) & (USD Million)
    Table 75. Asia-Pacific Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Application (2017-2022) & (USD Million)
    Table 76. Asia-Pacific Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Application (2023-2028) & (USD Million)
    Table 77. Asia-Pacific Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Region (2017-2022) & (USD Million)
    Table 78. Asia-Pacific Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Region (2023-2028) & (USD Million)
    Table 79. South America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Type (2017-2022) & (USD Million)
    Table 80. South America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Type (2023-2028) & (USD Million)
    Table 81. South America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Application (2017-2022) & (USD Million)
    Table 82. South America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Application (2023-2028) & (USD Million)
    Table 83. South America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Country (2017-2022) & (USD Million)
    Table 84. South America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Country (2023-2028) & (USD Million)
    Table 85. Middle East & Africa Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Type (2017-2022) & (USD Million)
    Table 86. Middle East & Africa Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Type (2023-2028) & (USD Million)
    Table 87. Middle East & Africa Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Application (2017-2022) & (USD Million)
    Table 88. Middle East & Africa Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Application (2023-2028) & (USD Million)
    Table 89. Middle East & Africa Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Country (2017-2022) & (USD Million)
    Table 90. Middle East & Africa Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Country (2023-2028) & (USD Million)
List of Figures
    Figure 1. Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Picture
    Figure 2. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Share by Type in 2021
    Figure 3. Stimulants
    Figure 4. Non-stimulants
    Figure 5. Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Share by Application in 2021
    Figure 6. Pediatric and Adolescents Picture
    Figure 7. Adults Picture
    Figure 8. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size, (USD Million): 2017 VS 2021 VS 2028
    Figure 9. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Forecast (2017-2028) & (USD Million)
    Figure 10. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Share by Region (2017-2028)
    Figure 11. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Share by Region in 2021
    Figure 12. North America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)
    Figure 13. Europe Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)
    Figure 14. Asia-Pacific Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)
    Figure 15. South America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)
    Figure 16. Middle East and Africa Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)
    Figure 17. Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Drivers
    Figure 18. Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Restraints
    Figure 19. Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Trends
    Figure 20. Pfizer Recent Developments and Future Plans
    Figure 21. GSK Recent Developments and Future Plans
    Figure 22. Eli Lilly Recent Developments and Future Plans
    Figure 23. Novartis Recent Developments and Future Plans
    Figure 24. Johnson & Johnson Recent Developments and Future Plans
    Figure 25. Mallinckrodt Recent Developments and Future Plans
    Figure 26. Hisamitsu Recent Developments and Future Plans
    Figure 27. UCB Recent Developments and Future Plans
    Figure 28. Takeda Recent Developments and Future Plans
    Figure 29. Purdue Pharma Recent Developments and Future Plans
    Figure 30. Impax Laboratories Recent Developments and Future Plans
    Figure 31. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Share by Players in 2021
    Figure 32. Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021
    Figure 33. Global Top 3 Players Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Share in 2021
    Figure 34. Global Top 10 Players Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Share in 2021
    Figure 35. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)
    Figure 36. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Share by Type in 2021
    Figure 37. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share Forecast by Type (2023-2028)
    Figure 38. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Share by Application in 2021
    Figure 39. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share Forecast by Application (2023-2028)
    Figure 40. North America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Sales Market Share by Type (2017-2028)
    Figure 41. North America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Sales Market Share by Application (2017-2028)
    Figure 42. North America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Share by Country (2017-2028)
    Figure 43. United States Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 44. Canada Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 45. Mexico Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 46. Europe Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Sales Market Share by Type (2017-2028)
    Figure 47. Europe Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Sales Market Share by Application (2017-2028)
    Figure 48. Europe Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Share by Country (2017-2028)
    Figure 49. Germany Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 50. France Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 51. United Kingdom Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 52. Russia Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 53. Italy Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 54. Asia-Pacific Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Sales Market Share by Type (2017-2028)
    Figure 55. Asia-Pacific Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Sales Market Share by Application (2017-2028)
    Figure 56. Asia-Pacific Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Share by Region (2017-2028)
    Figure 57. China Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 58. Japan Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 59. South Korea Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 60. India Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 61. Southeast Asia Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 62. Australia Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 63. South America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Sales Market Share by Type (2017-2028)
    Figure 64. South America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Sales Market Share by Application (2017-2028)
    Figure 65. South America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Share by Country (2017-2028)
    Figure 66. Brazil Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 67. Argentina Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 68. Middle East and Africa Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Sales Market Share by Type (2017-2028)
    Figure 69. Middle East and Africa Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Sales Market Share by Application (2017-2028)
    Figure 70. Middle East and Africa Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Share by Country (2017-2028)
    Figure 71. Turkey Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 72. Saudi Arabia Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 73. UAE Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 74. Methodology
    Figure 75. Research Process and Data Source

Research Methodology

Client Requirements

Review and analyze client requirements

Discussion of all the project requirements and queries

Flexibility Check

Project Feasibility Analysis

Finalizing tentative research programme

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

Determination of key drivers, restraints, challenge, and opportunity

Identifies market needs and trends

Market Size Estimation & Forecast

Estimation of historical data based on secondary and primary data

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

Consideration of geography, region-specific product/service demand for region segments

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

Data Source

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

Collection of data

Cumulating and collating the essential qualitative and quantitative data

Generation of report in client requested format by research analysts

Reviews by expert analysts

Final quality check

Clarifying queries

Receiving feedback

Ensuring satisfaction

01 Identification of data

This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
02 Evaluation of Market Dynamic

This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
03 Collection of Data

This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
04 Collaboration of Data

This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis

This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

Companies Mentioned

Pfizer
GSK
Eli Lilly
Novartis
Johnson & Johnson
Mallinckrodt
Hisamitsu
UCB
Takeda
Purdue Pharma
Impax Laboratories

Related Reports

Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market 2021 by Company, Regions, Type and Application, Forecast to 2026

Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market 2021 by Company, Regions, Type and Application, Forecast to 2026

date 21 Feb 2021

date Medical Care

The Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Product Tags

attention deficit hyperactivity disorder adhd therapeutics

Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics

Purchase Options

Single User License

USD3480.00

Multi User License

USD5220.00

Corporate Users License

USD6960.00

Add To Cart

Buy Now

Popular Product Keywords

AI
semiconductor
electron
5G
artificial intelligence
Battery
new energy
We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.

Speak to our analyst >>
Our Clients
What We Can Provide?

With better results and higher quality products,Our professional reports can achieve four things:
- Insight into the industry market information
- Analyze market development needs
- Prospects for future development
- Develop industry investment strategy
Digging deeper into global industry information and providing market strategies.

Contact Us >>